Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy—EORTC Infectious Diseases Group Trial XV
Authors:
- Winfried V. KernWKWinfried V. Kern
- Oscar MarchettiOMOscar Marchetti
- Lubos DrgonaLDLubos Drgona
- Hamdi AkanHAHamdi Akan
- Mickel AounMAMickel Aoun
- Murat AkovaMAMurat Akova
- Robrecht de BockRBRobrecht de Bock
- Marianne PaesmansMPMarianne Paesmans
- Claudio ViscoliCVClaudio Viscoli
- Thierry CalandraTCThierry Calandra
- 20 March 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (9) , 1149-1156
Abstract
Purpose: This double-blind, multicenter trial compared the efficacy and safety of a single daily oral dose of moxifloxacin with oral combination therapy in low-risk febrile neutropenic patients with cancer.Patients and Methods: Inclusion criteria were cancer, febrile neutropenia, low risk of complications as predicted by a Multinational Association for Supportive Care in Cancer (MASCC) score > 20, ability to swallow, and ≤ one single intravenous dose of empiric antibiotic therapy before study drug treatment initiation. Early discharge was encouraged when a set of predefined criteria was met. Patients received either moxifloxacin (400 mg once daily) monotherapy or oral ciprofloxacin (750 mg twice daily) plus amoxicillin/clavulanic acid (1,000 mg twice daily). The trial was designed to show equivalence of the two drug regimens in terms of therapy success, defined as defervescence and improvement in clinical status during study drug treatment (< 10% difference).Results: Among the 333 patients evaluated in an intention-to-treat analysis, therapy success was observed in 80% of the patients administered moxifloxacin and in 82% of the patients administered combination therapy (95% CI for the difference, −10% to 8%, consistent with equivalence). Minor differences in tolerability, safety, and reasons for failure were observed. More than 50% of the patients in the two arms were discharged on protocol therapy, with 5% readmissions among those in either arm. Survival was similar (99%) in both arms.Conclusion: Monotherapy with once daily oral moxifloxacin is efficacious and safe in low-risk febrile neutropenic patients identified with the help of the MASCC scoring system, discharged early, and observed as outpatients.Keywords
This publication has 61 references indexed in Scilit:
- Febrile neutropenia in French emergency departments: results of a prospective multicentre surveyCritical Care, 2010
- Prevalence and Risk Factors for Selection of Quinolone-Resistant Escherichia coli Strains in Fecal Flora of Patients Receiving Quinolone TherapyAntimicrobial Agents and Chemotherapy, 2009
- Safety Profile of the Respiratory Fluoroquinolone MoxifloxacinDrug Safety, 2009
- Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital dischargeSupportive Care in Cancer, 2008
- Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practiceSupportive Care in Cancer, 2007
- Antibiotic prophylaxis in neutropenic patientsCancer, 2006
- Risk Assessment and Treatment of Low-Risk Patients with Febrile NeutropeniaClinical Infectious Diseases, 2006
- Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index scoreSupportive Care in Cancer, 2004
- Outpatient Therapy for Febrile NeutropeniaPharmacoEconomics, 2003
- MoxifloxacinDrugs, 1999